Cardiol Therapeutics Inc. (CRDL) vs Korsana Biosciences, Inc. (KRSA)
A side-by-side comparison of Cardiol Therapeutics Inc. and Korsana Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRDL
Cardiol Therapeutics Inc.
$1.31HealthcareDelayed quote: Oct 6, 2026, 10:54 AM EDT
KRSA
Korsana Biosciences, Inc.
$30.77HealthcareDelayed quote: Oct 6, 2026, 10:49 AM EDT
Total return — CRDL vs KRSA
growth of $100 · dividends reinvested · last 8yCRDL -70.0% (-14.0%/yr)KRSA -98.2% (-39.7%/yr)CRDL compounded faster over this window
Log scale — wide-divergence pair
CRDL KRSA
CRDL vs KRSA: by the numbers
- •CRDL is the larger company ($151M vs $144M market cap).
- •Both run net losses; CRDL's is the smaller (0.00% vs -353.00% net margin).
Metrics side by side
Valuation
| Metric | CRDL | KRSA |
|---|---|---|
| P/S ratio | N/A | 75.80 |
| P/B ratio | 8.92 | 28.31 |
Profitability
| Metric | CRDL | KRSA |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -239.78% |
| Net margin | 0.00% | -353.00% |
| ROE | -155.34% | -131.85% |
| ROIC | -165.56% | -134.15% |
Growth (annualized)
| Metric | CRDL | KRSA |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -11.98% |
| Total return CAGR (5Y) | -18.36% | -40.41% |
Frequently asked
- How have CRDL and KRSA total returns compared?
- Over the past 5 years, CRDL delivered -18.36% and KRSA delivered -40.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.